Drawing on current data and clinical experience, Dr Wilkins highlights the importance of thoughtful patient selection and lesion-specific decision-making to maximize outcomes.
Drawing on current data and clinical experience, Dr Wilkins highlights the importance of thoughtful patient selection and lesion-specific decision-making to maximize outcomes.
Dr Wahood discusses trends reshaping the landscape of mechanical thrombectomy for acute ischemic stroke, particularly in patients with atrial fibrillation.
Dr Wahood discusses trends reshaping the landscape of mechanical thrombectomy for acute ischemic stroke, particularly in patients with atrial fibrillation.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr. Srini Tummala outlines the essential components of a high-quality noninvasive vascular assessment for patients with chronic limb-threatening ischemia.
Dr. Srini Tummala outlines the essential components of a high-quality noninvasive vascular assessment for patients with chronic limb-threatening ischemia.
Despite advances, women with AAA continue to experience disproportionately higher mortality rates and remain significantly underrepresented in clinical trials.
Despite advances, women with AAA continue to experience disproportionately higher mortality rates and remain significantly underrepresented in clinical trials.
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
The RED 72 SILVER LABEL devices are reperfusion catheters designed for acute ischemic stroke. Direct aspiration with RED 72 SILVER LABEL can provide a fast, frontline option for acute ischemic stroke. The COMPASS Trial has shown...
The RED 72 SILVER LABEL devices are reperfusion catheters designed for acute ischemic stroke. Direct aspiration with RED 72 SILVER LABEL can provide a fast, frontline option for acute ischemic stroke. The COMPASS Trial has shown...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Key Highlights
The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.
With five different lengths and six different French sizes,...
Key Highlights
The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.
With five different lengths and six different French sizes,...
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
